SLXN vs. ALGS, SPRO, LVTX, AKTX, COEP, FBLG, DYAI, BLUE, KZR, and FGEN
Should you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Aligos Therapeutics (ALGS), Spero Therapeutics (SPRO), LAVA Therapeutics (LVTX), Akari Therapeutics (AKTX), Coeptis Therapeutics (COEP), FibroBiologics (FBLG), Dyadic International (DYAI), bluebird bio (BLUE), Kezar Life Sciences (KZR), and FibroGen (FGEN). These companies are all part of the "pharmaceutical products" industry.
Silexion Therapeutics vs.
Aligos Therapeutics (NASDAQ:ALGS) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
Silexion Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. Silexion Therapeutics' return on equity of 0.00% beat Aligos Therapeutics' return on equity.
Aligos Therapeutics presently has a consensus price target of $70.00, suggesting a potential upside of 1,141.35%. Silexion Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 443.48%. Given Aligos Therapeutics' higher possible upside, research analysts plainly believe Aligos Therapeutics is more favorable than Silexion Therapeutics.
Silexion Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics.
Aligos Therapeutics received 27 more outperform votes than Silexion Therapeutics when rated by MarketBeat users. Likewise, 67.44% of users gave Aligos Therapeutics an outperform vote while only 66.67% of users gave Silexion Therapeutics an outperform vote.
In the previous week, Silexion Therapeutics had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for Silexion Therapeutics and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.00 beat Silexion Therapeutics' score of -0.48 indicating that Aligos Therapeutics is being referred to more favorably in the media.
60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are owned by institutional investors. 8.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 33.0% of Silexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Aligos Therapeutics has a beta of 2.76, meaning that its stock price is 176% more volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
Summary
Aligos Therapeutics beats Silexion Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Silexion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silexion Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SLXN) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy SLXN Stock Free SLXN Stock Alerts